Monopar Therapeutics (NASDAQ:MNPR) Hits New 1-Year High – What’s Next?

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) reached a new 52-week high on Friday . The stock traded as high as $116.69 and last traded at $114.70, with a volume of 160911 shares. The stock had previously closed at $114.66.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Friday, July 17th. UBS Group set a $125.00 target price on Monopar Therapeutics in a research report on Thursday, July 23rd. Piper Sandler set a $105.00 target price on shares of Monopar Therapeutics in a research note on Tuesday, June 2nd. Zacks Research upgraded shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. Finally, Wall Street Zen downgraded shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, July 12th. Three research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $112.08.

Monopar Therapeutics Trading Down 5.5%

The stock has a market cap of $725.95 million, a P/E ratio of -57.03 and a beta of 1.46. The company’s 50 day moving average price is $85.45 and its two-hundred day moving average price is $68.31.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.41. On average, sell-side analysts anticipate that Monopar Therapeutics Inc. will post -2.82 earnings per share for the current year.

Institutional Investors Weigh In On Monopar Therapeutics

A number of hedge funds have recently modified their holdings of the business. Bank of America Corp DE raised its holdings in Monopar Therapeutics by 838.2% in the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after purchasing an additional 53,336 shares during the period. ADAR1 Capital Management LLC grew its holdings in Monopar Therapeutics by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after purchasing an additional 30,370 shares during the period. The Manufacturers Life Insurance Company bought a new stake in Monopar Therapeutics during the first quarter valued at about $250,000. Siren L.L.C. increased its position in Monopar Therapeutics by 27.2% in the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after buying an additional 57,820 shares in the last quarter. Finally, Sei Investments Co. increased its position in Monopar Therapeutics by 9.5% in the first quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after buying an additional 656 shares in the last quarter. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.